Induced Pluripotent Stem Cell Technology and Direct Conversion: New Possibilities to Study and Treat Parkinson's Disease

Reinhard Roessler, Erik Boddeke, Sjef Copray*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)

Abstract

Recent developments in in vitro disease modeling and regenerative medicine have placed induced pluripotent stem cells (iPSCs) in the center of attention as a unique source to study Parkinson's disease. After only 5 years of intensive research, human iPSCs can be generated without viral integration and under xeno-free conditions. This, combined with increasingly sophisticated methods to differentiate iPSCs into functional dopaminergic (DA) neurons, led us to recapitulate the most important findings concerning the use of iPSC technology as a prospective tool to treat symptoms of Parkinson's disease as well as to obtain insight in disease related cell pathogenesis. Moreover, we touch upon some of the latest discoveries in which patient-derived autologous DA neurons come into even more direct reach thanks to a method that allows transdifferentiation of fibroblasts into DA neurons.

Original languageEnglish
Pages (from-to)505-513
Number of pages9
JournalStem cell reviews and reports
Volume9
Issue number4
DOIs
Publication statusPublished - Aug-2013

Keywords

  • Induced pluripotent stem cells
  • Parkinson's disease
  • Dopaminergic neurons
  • In vitro disease modeling
  • Cell based therapy
  • Transdifferentiation
  • MIDBRAIN DOPAMINE NEURONS
  • HUMAN SOMATIC-CELLS
  • HUMAN IPS CELLS
  • HUMAN FIBROBLASTS
  • ALPHA-SYNUCLEIN
  • IN-VITRO
  • ES CELLS
  • DEFINED FACTORS
  • DIFFERENTIATION
  • GENERATION

Cite this